participating in healthylifestyle activities more frequently post-intervention when analyzed on the TTM continuum. Further studies are needed to analyze the most effective strategies to assist individuals in rural settings to make healthier lifestyle choices.

**FUNDING ACKNOWLEDGEMENTS:** No funding.

### 108

**Lurasidone in Children and Adolescents With Bipolar Depression Presenting With Mixed Features**

*Cynthia Siu, PhD1; Andrei Pikalov, MD, PhD2; Michael Tocco, PhD3; and Antony Loebel4*

1 Data Scientist, Data Science, COS & Associates Ltd., Hong Kong, HK  
2 Head of Global Medical Affairs, Sunovion Pharmaceuticals Inc., Fort Lee, NJ  
3 Senior Director, Medical Affairs, Sunovion Pharmaceuticals Inc., Marlborough, MA  
4 Chief Medical Officer, Sunovion Pharmaceuticals Inc., Fort Lee, NJ

**ABSTRACT:** Objective: To evaluate the efficacy and safety of lurasidone in the treatment of children and adolescents with bipolar depression presenting with mixed features.

**METHODS:** Patients 10 to 17 years of age, inclusive, with a DSM-IV-TR diagnosis of bipolar I depression, were randomized to 6 weeks of double-blind treatment with once-daily, flexible doses of lurasidone 20-80 mg or placebo. The presence of mixed features (subthreshold hypomanic symptoms) was defined as a YMRS score > 5 at study baseline. Efficacy analyses included change from baseline to week 6 in Children Depression Rating Scale, Revised (CDRS-R) score (the primary outcome), and Clinical Global Impressions, Bipolar Severity of Depression Score (CGI-BP-S), using mixed model for repeated measures (MMRM) analysis.

**RESULTS:** At baseline, mixed features were present in 54.2% of patients (lurasidone, n = 97/173; placebo, n = 89/170). Treatment with lurasidone (vs placebo) was associated with significantly greater reductions in CDRS-R scores at week 6 in the mixed features group (-21.5 vs -15.9; P < 0.01; effect size, 0.45), and in the group without mixed features (-20.4 vs -14.8; P < 0.01; effect size, 0.45). Likewise, lurasidone was associated with greater effect size (vs placebo) for reductions in CGI-BP-S scores at week 6 in the mixed features group (-1.6 vs -1.1; P < 0.001; effect size 0.57), and in the group without mixed features (-1.3 vs -1.0; P = 0.05; effect size 0.30). Rates of protocol-defined treatment-emergent hypomania or mania were similar for lurasidone and placebo in patients with mixed features (lurasidone 8.2% vs. placebo 9.0%) and without mixed features (lurasidone 1.3% vs. placebo 3.7%).

**CONCLUSIONS:** In this post-hoc analysis, lurasidone was found to be efficacious for treating child and adolescent patients with bipolar depression presenting with mixed features (assessed cross-sectionally at study baseline). There was no increased risk of treatment-emergent mania observed in patients with or without mixed features.

**FUNDING ACKNOWLEDGEMENTS:** Sunovion Pharmaceuticals Inc.

### 109

**Comparative Efficacy and Tolerability of Lurasidone Versus Other Oral Atypical Antipsychotics for Pediatric Schizophrenia: A Network Meta Analysis**

*Celso Arango, MD, PhD1; Daisy Ng-Mak, PhD2; Elaine Finn, MPHm, MS2; Aidan Byrne, MS2; Krithika Rajagopalan, PhD3; and Antony Loebel, MD4*

1 Chair Child and Adolescent Psychiatry Department, Hospital General Universitario Gregorio Marañon, Universidad Complutense, IBERSAM, Madrid, Spain  
2 Senior Director, Global Health Economics & Outcomes Research, Sunovion Pharmaceuticals Inc, Marlborough, MA, USA  
3 QuintilesIMS, London, United Kingdom  
4 Head of Global HEOR, Global Health Economics and Outcomes Research, Sunovion Pharmaceuticals, Marlborough, MA  
5 Executive Vice President, Chief Medical Officer, Research & Development, Sunovion Pharmaceuticals Inc., Fort Lee, NJ, USA

**ABSTRACT:** Study Objective: This analysis assessed the relative efficacy and tolerability of lurasidone versus other atypical antipsychotics in the treatment of pediatric schizophrenia.

**METHODS:** A systematic literature review identified 13 randomized-controlled trials for the treatment of pediatric schizophrenia. A Bayesian network meta-analysis compared the efficacy and tolerability of the following atypical antipsychotics: aripiprazole, asenapine, clozapine, lurasidone, olanzapine, paliperidone, quetiapine, risperidone, and ziprasidone. Patients were 7-17 years old and trial duration ranged from 6-12 weeks. Outcomes included Positive and Negative Syndrome Scale (PANSS), Clinical Global Impressions-Severity (CGI-S), weight gain, all-cause treatment discontinuation, and extrapyramidal symptoms. Results from the fixed effect models